Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

I study is validation of Cell Therapeutics Inc.'s capabilities in acquiring attractive drug candidates, and designing and implementing a successful phase III trial," said James A. Bianco, M.D., CEO of Cell Therapeutics. "These data are consistent with the extensive experience with pixantrone in our phase I and phase II studies and demonstrate the ability to offer patients with advanced, relapsed NHL the potential to obtain a clinically meaningful response like a complete remission, despite having failed multiple other courses of chemotherapy or immuno-chemotherapy."

The EXTEND clinical trial is a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial was designed to examine the complete remission (CR) or unconfirmed complete remission (uCR) rate, overall survival (OS) and progression-free survival (PFS). The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.

CTI intends to further evaluate additional details of the study and will provide complete safety and progression-free survival information comparing treatment assignments which is currently being assembled for analysis.

Cell Therapeutics will be presenting at the Rodman & Renshaw Healthcare Conference on November 11, 2008 at 10:45 am Eastern time and a webcast will be available at http://www.celltherapeutics.com.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antit
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, announced the Company will ... Tuesday, April 28, 2015 to discuss the 1st quarter ... listen to the call by dialing 1-888-346-3479. International participants ... should ask to be joined into the IGI Laboratories, ...
(Date:4/24/2015)...  Span-America Medical Systems, Inc. (NASDAQ:  SPAN) announced ... second quarter results on Thursday, April 30, after the ... will conduct a conference call at 10:00 a.m. ... financial and operating results for the second quarter ended ... conference call will be available online at ...
(Date:4/24/2015)... -- Introduction of new "Elements" ... for radiosurgery/SBRT   The "Elements" strategy ... the workflow for difficult to treat indications in ... comes full circle with the introduction of automated ... enable on-the-fly generation of consistent treatment plans for ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2
... Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its ... will be issued on Friday, November 5th at 6:30 ... 8:30 a.m. Friday, November 5th - 8:30 a.m. E.D.T.If ... callers use:502-719-4466Password - DUSAA replay of the call will ...
... BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial -- CARMIEL, Israel, Nov. 2, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 2Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 3Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 4Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 5Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 6Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 7Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 8Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 9Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial 10
(Date:4/26/2015)... The grand celebration got off to a festive start with ... Deb then introduced Sandy Valentine, the wife of CCAR’s Executive ... his Walk for Recovery on the Appalachian Trail. ... gratitude to the volunteers via video. Board President Tom Kirk ... CCAR’s mission. Volunteer Manager Conrad Sienkiewicz read the names ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 In observance ... will join The Million Nets Pledge, a two-year pledge ... to protect refugee families with one million bednets by ... increased work with UN partners to protect children, refugees, ... malaria. , “There has been a large surge ...
(Date:4/25/2015)... NY (PRWEB) April 25, 2015 By definition, ... and data for the enterprise relying on their judgement and ... smoothly. But according to an article published in ... many times actually be doing a disservice to their responsibilities ... are dotted and t’s are crossed when it comes to ...
(Date:4/25/2015)... York New York (PRWEB) April 25, 2015 ... that Dr. Jerry Blaivas has been chosen by the New ... for his contributions to medicine in the field of Urology. ... the best in his speciality, Genito-Urinary diseases. He was ... specifically in the field of urology. Not only did ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Constellations Recovery ... residence in Westchester County. Just 35 miles from New ... individuals back into everyday life while recovering from addiction. ... 7, 2015, will allow therapists, doctors and treatment centers ... learn more about the opportunities offered by Constellations Recovery., ...
Breaking Medicine News(10 mins):Health News:The Connecticut Community for Addiction Recovery (CCAR) honors its volunteers during National Volunteer Recognition Week. 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3
... number of cardiac patients by 2020 if Indians do not ... above warning has been issued by leading Cardiologists in the ... number of diabetic patients are contributing to the increasing incidence ... suffers from heart diseases. ,'Since heart disease is ...
... a penis enlargement procedure. Too much hype and hoopla ... the internet and spam mails, // has ... to the researchers, it is still under weather down ... with the outcome. ,Nim Christopher, a urologist ...
... due to the new Medicare drug plan. Each plan has its ... These plans require the patients to obtain prior authorization from the ... prior authorization for different drugs. Most states have at least 40 ... make the system complicated and delay the access of the medication. ...
... Health Organisation) today projected that by 2020 road accidents ... outranking public health issues like tuberculosis, diarrhoea and HIV/AIDS.// ... are expected to increase from 135,000 in 2000 to ... from road crashes, according to a WHO report 'World ...
... in the latest edition of the British Dental Journal says ... the knowledge of the early signs and symptoms of the ... at University College, London and Guy's, King's and St Thomas' ... heard of oral cancer or mouth cancer as compared to ...
... a wake up call to obese baby boomers, who could be ... ,Dr. Beth Abramson, foundation spokesperson and cardiologist told CTV."It was ... have soared by nearly 60 per cent and a staggering 52 ... the group between 45 and 60, are not as fit as ...
Cached Medicine News:Health News:Change In Lifestyle Recommended To Avoid Cardiac Disease 2Health News:Medicare Drug Plans Are Onerous and Restrictive 2Health News:Road accidents greater threat than AIDS, TB: WHO 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: